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ABSTRACT
OBJECTIVES
To derive and validate risk prediction algorithms to
estimate the risk of covid-19 related mortality and
hospital admission in UK adults after one or two
doses of covid-19 vaccination.
DESIGN
Prospective, population based cohort study using
the QResearch database linked to data on covid-19
vaccination, SARS-CoV-2 results, hospital
admissions, systemic anticancer treatment,
radiotherapy, and the national death and cancer
registries.
SETTINGS
Adults aged 19-100 years with one or two doses of
covid-19 vaccination between 8 December 2020 and
15 June 2021.
MAIN OUTCOME MEASURES
Primary outcome was covid-19 related death.
Secondary outcome was covid-19 related hospital
admission. Outcomes were assessed from 14 days
after each vaccination dose. Models were fitted in
the derivation cohort to derive risk equations using
a range of predictor variables. Performance was
evaluated in a separate validation cohort of general
practices.
RESULTS
Of 6 952 440 vaccinated patients in the derivation
cohort, 5 150 310 (74.1%) had two vaccine doses. Of
2031 covid-19 deaths and 1929 covid-19 hospital
admissions, 81 deaths (4.0%) and 71 admissions
(3.7%) occurred 14 days or more after the second
vaccine dose. The risk algorithms included age, sex,
ethnic origin, deprivation, body mass index, a range
of comorbidities, and SARS-CoV-2 infection rate.
Incidence of covid-19 mortality increased with age
and deprivation, male sex, and Indian and Pakistani
ethnic origin. Cause specific hazard ratios were
highest for patients with Down’s syndrome (12.7-fold
increase), kidney transplantation (8.1-fold), sickle
cell disease (7.7-fold), care home residency (4.1-fold),
chemotherapy (4.3-fold), HIV/AIDS (3.3-fold), liver
cirrhosis (3.0-fold), neurological conditions (2.6-fold),
recent bone marrow transplantation or a solid organ
transplantation ever (2.5-fold), dementia (2.2-fold),
and Parkinson’s disease (2.2-fold). Other conditions
with increased risk (ranging from 1.2-fold to 2.0-fold
increases) included chronic kidney disease, blood
cancer, epilepsy, chronic obstructive pulmonary
disease, coronary heart disease, stroke, atrial
fibrillation, heart failure, thromboembolism,
peripheral vascular disease, and type 2 diabetes. A
similar pattern of associations was seen for covid-19
related hospital admissions. No evidence indicated
that associations differed after the second dose,
although absolute risks were reduced. The risk
algorithm explained 74.1% (95% confidence interval
71.1% to 77.0%) of the variation in time to covid-19
death in the validation cohort. Discrimination was
high, with a D statistic of 3.46 (95% confidence
interval 3.19 to 3.73) and C statistic of 92.5.
Performance was similar after each vaccine dose. In
the top 5% of patients with the highest predicted
covid-19 mortality risk, sensitivity for identifying
covid-19 deaths within 70 days was 78.7%.
CONCLUSION
This population based risk algorithm performed well
showing high levels of discrimination for identifying
those patients at highest risk of covid-19 related
death and hospital admission after vaccination.
Introduction
During the first waves of the covid-19 pandemic
(March 2020 to August 2020), before the introduction
of vaccines, it was essential to be able to identify
people at highest risk of adverse outcomes if they
were infected with SARS-CoV-2. The QCovid risk
assessment tool for predicting risk of covid-19 related
death or hospital admission based on individual
characteristics was developed,1 independently
externally validated,2 and found to have performed
well at identifying those individuals at high risk of
severe outcomes from covid-19. The tool was used in
England to identify patients at high risk of severe
covid-19 outcomes, adding an additional 1.5 million
people to the national shielded patient list in
February 2021 and, on a UK basis, prioritising them
for vaccination (if they had not already been offered
the vaccine on account of their age or occupation).3
Since then, clinical trials of covid-19 vaccinations
have demonstrated safety and efficacy in healthy
volunteers4 -6 and have been rolled out to the adult
UK population, beginning with the most elderly
groups (aged ≥90 years) and those people most at
risk. Although vaccines have been found to be highly
effective in trials andobservational studies, a residual
risk of serious covid-19 outcomes (in particular,
hospital admission or death) remains after
vaccination, despite allowing adequate time for
immunity to develop. The risk of a severe outcome
in vaccinated groups includes the risk of exposure,
the risk of a breakthrough infection if exposed, and
the risk of a breakthrough infection becoming severe.
However, the relevant risk factors are currently
unknown because clinical trials have not included
many people in whom vaccine response might be
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suboptimal (eg, elderly people, people with complex comorbidities
(eg, in receipt of solid organ transplants or immunosuppressive
treatment for autoimmune disorders), or patients with cancer
receiving chemotherapy or radiotherapy7).
Therefore, vaccinated individuals at highest risk of consequent
severe outcomes such as covid-19 related hospital admission or
death need to be identified urgently. A risk stratification tool for
the vaccinated population would enable identification of patients
to prioritise for targeted, early interventions once these become
available—includingbooster vaccination andpreventive treatments
such as passive antibody delivery (for either prophylactic or
therapeutic use). Risk stratification tools also provide a robust
pragmatic mechanism for avoiding unnecessary lifestyle
precautions, investigations, and therapeutic interventions for those
individuals whose risk is relatively low, but who might perceive it
to be much higher.
Wedeveloped andvalidated twonewQCovid risk algorithms, based
on data from the second pandemic wave in England, to identify
those groups at highest risk of severe covid-19 outcomes: QCovid2
(basedonunvaccinatedpatients) andQCovid3 (basedonvaccinated
patients). Given the nature of the pandemic, the speed of the
vaccinationprogramme, the relaxation of lockdownmeasures, and
the urgent need to develop national policy, this work had to be
undertaken during the pandemic period and national vaccination
programme, and therefore included people who had only one
vaccination dose as well as those who were fully vaccinated.
Methods
Data sources
We used the QResearch database (version 46) of 12 million patients
with personal, clinical, and drug data that have been used for
clinical1 8 and drug safety research.9 10 QResearch is linked to
multiple datasets at individual patient level. For this analysis, we
used the National Immunisation Database of covid-19 vaccinations
to identify data on vaccine date and doses for all people vaccinated
in England. For hospital admissions, we used the linked Hospital
Episode Statistics dataset supplemented by the more regularly
updated SecondaryUsers Service data.Wealso obtained and linked
the following datasets: national data for mortality; SARS-CoV-2
infection; systemic anticancer treatment; radiotherapy treatment
datasets; and national cancer registry data.
Study design and period for vaccinated cohort
We undertook a prospective cohort study of vaccinated individuals
from 8 December 2020 (the earliest vaccination date in England) to
15 June 2021 (the latest date for which data were available at the
time of the analysis). We considered outcomes after the first and
secondvaccinationdoses. The cohort includedpeoplewho received
one or two doses of a covid-19 vaccine during the study period.
Individuals were followed from 14 days after receiving each vaccine
dose until they had the outcome of interest, died, or reached the
end of the study period. Use of follow-up time after the first dose
and after the second dose is described below.
Inclusion criteria for vaccinated cohort
We included all adults aged 19-100 years who had one or two doses
of the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) or BNT162b2
(Pfizer-BioNTech) vaccine during the study period. Both these
vaccinations require two doses for full vaccination. People were
excluded from the analysis of hospital outcomes if they had a
covid-19 associatedhospital admissionbefore their start of follow-up
(14 days after the first or second dose of vaccination).
Outcomes for vaccinated cohort
The primary outcome was time to covid-19 related death (either in
or out of hospital) as recorded on the death certification, or death
within 28 days of a SARS-CoV-2 infection confirmed by reverse
transcription polymerase chain reaction (RT-PCR). The secondary
outcome was time to hospital admission with covid-19, defined as
either confirmed or suspected covid-19 on ICD-10 (international
classification of diseases, 10th revision) codes U071 and U072, or
new hospital admission associated with a confirmed SARS-CoV-2
infection in the preceding 14 days. These outcome definitions are
also used for covid-19 death and hospital admission in the UK.11
Both outcomes were assessed from 14 days or more after the first
and second doses of vaccination, from which time we considered
it was reasonable to expect some immunity.
Predictor variables for vaccinated cohort
Candidate predictor variables likely to be associated with increased
risk of covid-19 death or hospital admission were identified from
the original QCovid protocol12 and from previous studies.1 8 13 The
variables were vaccine dose (first or second), age, sex, ethnic origin,
Townsend deprivation score (an area level score based on postcode
where higher scores indicate higher levels of deprivation14), body
mass index,13 domicile (care home, homeless, neither), chronic
kidney disease, chemotherapy in previous 12 months, type 1 or type
2 diabetes (with glycated haemoglobin (HbA1c) levels <59 or ≥59
mmol/mol), blood cancer, bone marrow transplantation in past six
months, respiratory cancer, radiotherapy in past six months, solid
organ transplantation, chronic obstructive pulmonary disease,
asthma, rare lung diseases (cystic fibrosis, bronchiectasis, or
alveolitis), pulmonaryhypertensionorpulmonary fibrosis, coronary
heart disease, stroke, atrial fibrillation, heart failure, venous
thromboembolism, peripheral vascular disease, congenital heart
disease, dementia, Parkinson’s disease, epilepsy, rare neurological
conditions (motor neurone disease, multiple sclerosis, myasthenia
gravis, or Huntington’s chorea), cerebral palsy, osteoporotic
fracture, rheumatoid arthritis or systemic lupus erythematosus,
liver cirrhosis, bipolar disorder or schizophrenia, inflammatory
bowel disease, sickle cell disease, HIV/AIDS, severe combined
immunodeficiency, and record of a SARS-CoV-2 positive test result
before cohort entry.
To account for changing infection rates during the study period
(since the vaccination programme was started during the second
pandemic wave in England), we calculated a seven-day moving
average of the background rates of positive SARS-CoV-2 tests per
100000people, usingpublishedEnglishnational data.15 We linked
the rate to the date of cohort entry for each individual (that is, 14
days after each vaccine dose).
We defined predictors using information recorded in primary care
electronic health records at the start of follow-up at 14 days after
the first dose, except for chemotherapy, radiotherapy, and
transplantations, which were based on linked data related to
systemic anticancer and radiotherapy treatment, Hospital Episode
Statistics data, and Secondary Users Service data. For all predictor
variables, we used the most recently available value at the cohort
entry date.
Model development
To maximise the number of events after second dose of vaccine, we
used all 1336 practices with linked data available up to 15 June 2021
at the time of model development. We subsequently validated it in
the remaining 182 practices once the updated linked data to 15 June
2021 became available a few weeks later.
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People entered the cohort at 14 days after their first vaccination
dose. We used a landmarking approach16 to handle the time
dependent dose variable, because some people contributed
follow-up time after their second dose as well as after their first
dose. For people with only one dose, we followed them up until
they had the event of interest, died, or reached the study end. For
those with two vaccination doses, we split follow-up time into two
periods. Period 1 included the time from 14 days after their first
vaccination dose until 14 days after their second dose (therefore,
outcomes during the first 14 days after the second dose were
attributed to the first dose). Period 2 included time from 14 days
after their second dose until they had the event of interest, died, or
reached the study end. We fitted all models using combined data
from follow-up after the first and second doses, with dose number
entered into the model as a predictor.
Wedeveloped the riskmodels using cause specific Coxproportional
hazard models to calculate hazard ratios and develop risk scores
accounting for the competing risk of death due to other causes. A
hazard ratio is a measure of the rate at which a particular outcome
happens in one group relative to the rate at which it happens in
another group over time. We fitted two cause specific Cox models
to derive a risk algorithm for our primary outcome—one for covid-19
deaths and one for deaths due to other causes, censoring patients
with the respective competing event. For our secondary outcome,
we fitted one model for covid-19 admission and another model for
all cause mortality (excluding deaths occurring after a covid-19
admission).
We used second degree fractional polynomials to model non-linear
associations for continuousvariables includingSARS-Cov-2 infection
rates, age, body mass index, and Townsend deprivation score.14
We fitted the models to the complete cases (that is, with no missing
values for predictor variables) to derive the fractional polynomial
terms. We used multiple imputation with chained equations to
imputemissing values for ethnic origin, Townsend score, bodymass
index, and HbA1c. We carried out five imputations and fitted the
prediction models in each imputed dataset, and used Rubin’s rules
to combine the model parameter estimates across the imputed
datasets.17
We retained variables in the final models that were significant at
the 5% level (taking account of the clustered nature of the data) or
when adjusted cause specific hazard ratios for categorical variables
were more than 1.1. Clinically similar variables with low numbers
of events, such as bone marrow and solid organ transplantation,
were combined. We examined interactions between predictor
variables and age, as well as interactions between vaccine dose and
age, body mass index, ethnic origin, deprivation, and each
comorbidity. Furthermore, we derived estimates of the cumulative
incidence function for covid-19 mortality accounting for the
competing risk of death from other causes by combining estimates
obtained from the two cause specific Cox models using an
appropriate formula.18 The same method was used to derive the
cumulative incidence function for covid-19 hospital admission,
accounting for competing risk of death. These final algorithms for
predicting absolute risk in vaccinated individuals are referred to as
QCOVID3.18
We developed an additional model restricted to vaccinated patients
with a positive SARS-CoV-2 test result after vaccination. This model
separately quantified the risk of severe outcomes (mortality and
admission) in individuals with a record of infection.
Model evaluation
We evaluated model performance in the separate validation cohort.
We used multiple imputation to replace missing values for ethnic
origin, bodymass index, andTownsendscore; the imputationmodel
usedwas the sameas that used in thederivation cohort.Weapplied
the final risk equations to calculate the risk scores for each outcome
accounting for competing risks, and calculated aC indexaccounting
for competing risks using R.19 We also calculated R2 values and D
statistics20 although these statistics were only available for the
cause specific outcomes.
We assessed model calibration in the validation cohort accounting
for competing risks by comparing mean predicted risks with the
observed cumulative incidence function by twentieths of predicted
risk.21 A model is well calibrated if predicted risks closely
approximate the observed risks. We calculated each metric in the
whole validation cohort, separately for individualswhohad received
one and two vaccination doses, and in subgroups for age and sex
(ethnic groups had too few patients to undertake analyses).
Risk stratification
We applied the algorithms to the validation cohort to define the
centile thresholds based on absolute risk using the prevailing
SARS-CoV-2 rate 14 days after the date of each vaccination dose.
Sensitivitywas calculatedas the total cumulativenumber of patients
with a risk score above the risk threshold with a covid-19 death by
70 days divided by the total cumulative number of patients with a
covid-19 death by 70 days.
QCovid2 model in the unvaccinated cohort
We also developed and evaluated two additional models (QCovid2)
based on a cohort of unvaccinated people aged 19-100 years and
observed between 1 September 2020 and 31 May 2021 but censoring
people who were subsequently vaccinated on the date of their first
vaccination.Additional variablesnot included in theoriginalQCovid
model were used, such as inflammatory bowel disease and levels
of diabetes control according to HbA1c measurements. We also
examined separate variables for sickle cell disease, HIV/AIDs,
immunodeficiency conditions, and a refined definition of severe
mental illness (to determine the contributionofmoderate and severe
depression). The first model included all unvaccinated patients
(restricting to the time before vaccination for those who were
subsequently vaccinated). The second model was restricted to
unvaccinated patients with a positive SARS-CoV-2 test result, to
separately quantify the risk of SARS-CoV-2 infection from the risk
of severe outcomes (covid-19 mortality and admission) in those
people with a positive test result. These final algorithms for
predicting absolute risk in unvaccinated individuals are referred to
as QCovid2.
Reporting
Stata (version 17) and R were used for analyses. The study adhered
to the TRIPOD (transparent reporting of a multivariable prediction
model for individual prognosis or diagnosis) statement for
reporting.22
Patient and public involvement
Patientswere involved in framing the research question, identifying
predictors, and in developing plans for design and implementation
of the study.
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Characteristics of the vaccinated cohort
Table 1 shows the characteristics of the 6952 440vaccinatedpatients
in the derivation cohort, of whom 4 026 592 (57.9%) had the
Oxford-AstraZeneca vaccine and 2 925 848 (42.1%) had the
Pfizer-BioNTech vaccine. Overall, the mean age was 52 years
(standard deviation 17.7), 3 321 247 (47.8%) were men, and 5 150 310
(74.1%) had two vaccine doses. The median follow-up time was 72
days (interquartile range 59-77) after the first dose and 35 (18-53)
days after the seconddose.Of 2031 covid-19 relateddeaths and 1929
covid-19 related hospital admissions, 81 deaths and 71 admissions
occurred 14 days or more after the second vaccine dose. Of the 1929
patients in hospital, 446 (23.1%) subsequently died. Supplementary
table 1 shows corresponding results for the 626 656 vaccinated
patients in the validation cohort, of whom 174 had a covid-19 death
and 179 had a covid-19 hospital admission. Of these, 10 deaths and
seven admissions occurred 14 days or more after the second vaccine
dose.
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Table 1 | Personal and medical characteristics for the derivation cohort and covid-19 related death or hospital admission 14 days or more after vaccination.
Data are number (%) unless stated otherwise
Covid-19 admissions (n=1929)Covid-19 deaths (n=2031)Total (n=6 952 440)Characteristics
Sex:
983 (50.96)981 (48.30)3 631 193 (52.23)Women
946 (49.04)1050 (51.70)3 321 247 (47.77)Men
77.36 (14.84)84.48 (9.15)52.46 (17.73)Mean age (SD)
−0.05 (2.92)−0.25 (2.76)−0.17 (2.98)Mean Townsend deprivation score (SD)
27.90 (6.18)26.04 (5.89)27.30 (5.64)Mean body mass index (SD)
52.93 (22.38)60.05 (21.06)21.34 (22.80)
Mean background SARS-CoV-2 daily infection
rate per 100 000 population (SD)
78 (4.04)147 (7.24)414 163 (5.96)No of patients with SARS-Co-2 positive test
result before vaccination
Age (years):
19 (0.98)—771 125 (11.09)<30
43 (2.23)—1 105 120 (15.90)30-39
71 (3.68)9 (0.44)1 218 902 (17.53)40-49
121 (6.27)38 (1.87)1 402 707 (20.18)50-59
160 (8.29)81 (3.99)1 090 778 (15.69)60-69
377 (19.54)327 (16.10)860 179 (12.37)70-79
830 (43.03)960 (47.27)414 752 (5.97)80-89
308 (15.97)614 (30.23)88 877 (1.28)≥90
Covid-19 vaccination:
1858 (96.32)1947 (95.86)1 802 130 (25.92)1 dose
71 (3.68)81 (4.14)5 150 310 (74.08)2 doses
Ethnic origin:
1466 (76.00)1512 (74.45)4 781 050 (68.77)White
51 (2.64)44 (2.17)202 528 (2.91)Indian
46 (2.38)27 (1.33)111 873 (1.61)Pakistani
14 (0.73)8 (0.39)81 197 (1.17)Bangladeshi
22 (1.14)13 (0.64)117 061 (1.68)Other Asian
13 (0.67)15 (0.74)48 486 (0.70)Caribbean
11 (0.57)4 (0.20)113 663 (1.63)Black African
——41 595 (0.60)Chinese
20 (1.04)15 (0.74)187 576 (2.70)Other
Chronic kidney disease:
1290 (66.87)1231 (60.61)6 597 783 (94.90)None
531 (27.53)662 (32.59)319 898 (4.60)Stage 3
56 (2.90)85 (4.19)17 914 (0.26)Stage 4
27 (1.40)45 (2.22)10 098 (0.15)Stage 5 only
10 (0.52)—2182 (0.03)Stage 5 with dialysis
15 (0.78)5 (0.25)4565 (0.07)Stage 5 with transplant
Chemotherapy:
1891 (98.03)1978 (97.39)6 911 085 (99.41)None in past 12 months
12 (0.62)9 (0.44)14 518 (0.21)Group A
25 (1.30)42 (2.07)25 087 (0.36)Group B
——1750 (0.03)Group C
Type 1 diabetes:
1919 (99.48)2023 (99.61)6 911 191 (99.41)No type 1 diabetes
——13 536 (0.19)HbA1c ≤59 mmol/mmol (≤7.5%)
9 (0.47)5 (0.25)27 276 (0.39)HbA1c >59 mmol/mol (>7.5%)
——437 (0.01)HbA1c not recorded
Type 2 diabetes:
1385 (71.80)1486 (73.17)6 375 340 (91.70)No type 2 diabetes
347 (17.99)382 (18.81)370 653 (5.33)HbA1c ≤59 mmol/mol (≤7.5%)
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Table 1 | Personal and medical characteristics for the derivation cohort and covid-19 related death or hospital admission 14 days or more after vaccination.
Data are number (%) unless stated otherwise (Continued)
Covid-19 admissions (n=1929)Covid-19 deaths (n=2031)Total (n=6 952 440)Characteristics
196 (10.16)159 (7.83)203 998 (2.93)HbA1c >59 mmol/mol (>7.5%)
——2449 (0.04)HbA1c not recorded
Other pre-existing health conditions:
67 (3.47)72 (3.55)46 748 (0.67)Blood cancer
7 (0.36)—1979 (0.03)
Bonemarrow transplantation in past 6months
or solid organ transplantation ever
19 (0.98)29 (1.43)17 401 (0.25)Respiratory cancer
16 (0.83)19 (0.94)12 011 (0.17)Radiotherapy in past 6 months
——3963 (0.06)Down’s syndrome
216 (11.20)278 (13.69)199 780 (2.87)Chronic obstructive pulmonary disease
456 (23.64)530 (26.10)318 851 (4.59)Coronary heart disease
282 (14.62)407 (20.04)193 710 (2.79)Stroke
399 (20.68)479 (23.58)222 783 (3.20)Atrial fibrillation
241 (12.49)308 (15.16)105 427 (1.52)Heart failure
140 (7.26)216 (10.64)158 464 (2.28)Venous thromboembolism
97 (5.03)131 (6.45)63 553 (0.91)Peripheral vascular disease
305 (15.81)631 (31.07)81 320 (1.17)Dementia
38 (1.97)84 (4.14)22 489 (0.32)Parkinson’s disease
61 (3.16)49 (2.41)109 204 (1.57)Epilepsy
18 (0.93)20 (0.98)27 312 (0.39)Rare neurological conditions
19 (0.98)27 (1.33)17 457 (0.25)Liver cirrhosis
——2073 (0.03)Sickle cell disease
——15 218 (0.22)HIV/AIDS
——3853 (0.06)Severe combined immunodeficiency
SD=standard deviation; HbA1c=glycated haemogoblin. Chemotherapy groups are defined in supplementary box A of reference 1.
QCovid3: associations of outcomes with predictor variables
The final risk algorithms for covid-19 mortality included age, sex,
ethnic origin, Townsend deprivation, body mass index, a range of
comorbidities, and SARS-CoV-2 infection rate. We did not find any
evidence of interactions between the dose variable and other
predictors (although we did find small numbers for some
pre-existing health conditions). Figure 1 and figure 2 show the
adjusted hazard ratios and 95% confidence intervals for predictor
variables included in the final cause specific models for covid-19
related deaths and hospital admissions. Supplementary figures 1-3
show the adjustedhazard ratios for the fractional polynomial terms
for age, body mass index, and background SARS-CoV-2 infection
rate, respectively. Hazard ratios increased with increasing age,
Townsend deprivation, and background rates of SARS-CoV-2
infection. We saw a J shaped association between body mass index
and rates of both hospital admission and mortality outcomes.
Supplementary figures 4 and 5 show the adjusted hazard ratios for
the competing events of non-covid-19 death and all cause deaths.
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Fig 1 | Use of QCovid3 model showing adjusted cause specific hazard ratios for covid-19 death after vaccination, mutually adjusted and adjusted for fractional polynomial
terms for age, body mass index, vaccination dose, and background infection rate at time of vaccination. CKD=chronic kidney disease; HbA1c=glycated haemogoblin
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Fig 2 | Use of QCovid3 model showing adjusted cause specific hazard ratios for covid-19 hospital admission after vaccination, mutually adjusted and adjusted for fractional
polynomial terms for age, body mass index, vaccination dose, and background infection rate at time of vaccination. CKD=chronic kidney disease; HbA1c=glycated haemogoblin
Covid-19 mortality incidence increased with age and deprivation,
male sex, and Indian and Pakistani ethnic origin. Hazard ratios
were highest for those with Down’s syndrome (12.7-fold increase),
kidney transplantation (8.1-fold), sickle cell disease (7.7-fold), care
home residency (4.1-fold), group B (3.6-fold) and group C
chemotherapy (4.3-fold), recent bone marrow transplantation or a
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solid organ transplantation ever (2.5-fold), HIV/AIDS (3.3-fold),
dementia (2.2-fold), Parkinson’s disease (2.2-fold), neurological
conditions (2.6-fold), and liver cirrhosis (3.0-fold). Other conditions
associated with increased covid-19 mortality included chronic
kidney disease, blood cancer, epilepsy, chronic obstructive
pulmonarydisease, coronaryheart disease, stroke, atrial fibrillation,
heart failure, thromboembolism, peripheral vascular disease, and
type 2 diabetes (with highest risks among those with HbA1c ≥59
mmol/mol (>7.5%)). The adjusted hazard ratio for covid-19 related
deathwas0.17 (95%confidence interval 0.13 to 0.22) after the second
vaccine dose (plus 14 days) compared with after the first vaccine
dose (plus 14 days).
We found similar patterns of associations between predictors and
the cause specific hazard for covid-19 admission (fig 2) except for
conditions with too few events for analysis (that is, sickle cell
disease, severe combined immunodeficiency, and HIV/AIDS).
Similarly, the adjusted hazard ratio of covid-19 related hospital
admission was 0.21 (95% confidence interval 0.16 to 0.27) after the
second dose compared with after the first dose.
Supplementary figure 6 shows the corresponding results for risk of
covid-19 death among the subgroup of patients with a SARS-CoV-2
positive test result. The associations for each factor in the restricted
model were similar to those of the main QCovid3 model apart from
ethnic origin (for which no significant associations were seen) and
conditions with too few events for analysis (sickle cell disease,
severe combined immunodeficiency, HIV/AIDS). All associations
with pre-existing health conditions reported are conditional on the
other predictors in the model and do not necessarily have a causal
interpretation.
QCovid3 model evaluation of performance
Table 2 shows theperformanceof the risk equations in the validation
cohort. TheQCovid3 algorithm for covid-19 relateddeath explained
74.1% (95% confidence interval 71.1% to 77.0%) of the variation in
time to covid-19 death, the Royston’s D statistic was 3.46 (3.19 to
3.73) and the Harrell’s C statistic was 92.5. Results were similar in
menandwomen.Corresponding results restricted to the first vaccine
dose were 71.3% (67.9% to 74.7%), 3.23 (2.96 to 3.50), and 93.6. The
results restricting to the validation cohort after the second vaccine
dose were similar but with wider confidence intervals owing to
smaller numbers. The values for the R2, D, and C statistics were
similar for the hospital admission equation. Supplementary table
2 shows the corresponding results for covid-19 death and hospital
admission by age band where performance tended to be lower in
the higher age bands.




65.7 (61.8 to 69.6)74.1 (71.1 to 77)R2
2.83 (2.59 to 3.08)3.46 (3.19 to 3.73)Royston’s D statistic
Women
86.894.4Harrell’s C statistic
66.4 (60.9 to 71.9)75.4 (71.6 to 79.3)R2
2.88 (2.52 to 3.23)3.59 (3.22 to 3.96)Royston’s D statistic
Men
83.690.4Harrell’s C statistic
64.9 (59.5 to 70.4)72.7 (68.5 to 76.9)R2
2.79 (2.45 to 3.12)3.34 (2.99 to 3.7)Royston’s D statistic
One dose of vaccine only
85.593.6Harrell’s C statistic
60 (55.2 to 64.7)71.3 (67.9 to 74.7)R2
2.5 (2.26 to 2.75)3.23 (2.96 to 3.5)Royston’s D statistic
Two doses of vaccine
79.381.7Harrell’s C statistic
72.1 (57.3 to 87)70 (54.5 to 85.6)R2
3.29 (2.08 to 4.51)3.13 (1.97 to 4.29)Royston’s D statistic
Harrell’s C statistic=time dependent area under the curve accounting for competing risks; confidence intervals could not be obtained.
Figure 3 shows the calibration plot for covid-19 related deaths and
figure4 shows the corresponding results for covid-19 relatedhospital
admission, both accounting for competing risks. Model calibration
was assessedby comparingmeanpredicted riskswith the observed
cumulative incidence function by twentieths of predicted risk21; a
model is well calibrated if predicted risks closely approximate the
observed risks. These plots showed reasonable correspondence
between observed and predicted cumulative incidences at 70 days
of follow-up. However, numbers of events were small in several
groups, and in thehigher twentiethswe saw slight under-prediction
for covid-19 death (fig 3) and in twentieths 17-19 for the admissions
outcome (fig 4). For example, in the top twentieth of predicted risks
for covid-19 death, the observed cumulative incidence was 0.28%
over 70 days (95% confidence interval 0.24% to 0.33%) and the
mean predicted risk was 0.25%.
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Fig 3 | Calibration of the QCovid3 risk model to predict covid-19 related death after vaccination. Data source: QResearch England, 8 December 2020 to 15 June 2021,
https://www.qresearch.org/
Fig 4 | Calibration of the QCovid3 risk model to predict covid-19 related hospital admission after vaccination. Data source: QResearch England, 8 December 2020 to 15 June
2021, https://www.qresearch.org/
QCovid3 risk stratification
Table 3 shows the percentage of covid-19 related deaths identified
by the QCovid3 mortality equation at different thresholds based on
centiles of predicted absolute risk in the validation cohort, using
the background SARS-CoV-2 infection rate associated with 14 days
after vaccination. For example, it shows that 78.7% of deaths
occurred in individuals in the top 5% for predicted absolute risk of
covid-19 death (predicted absolute risks at 70 days above 0.06%).
Individuals in the top 20% for predicted absolute risk of death
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accounted for 98.9% of deaths. Table 4 summarises the
characteristics of individuals at the highest predicted absolute risk
of covid-19 death (top 5%). Box 1 lists clinical examples of patients
and their predicted covid-19 risks (https://bmjSept2021.qcovid.org).
Table 3 | Sensitivity for covid-19 related death at 70 days’ follow-up in the validation cohort (consisting of 626 656 vaccinated patients with 174 covid-19
related deaths at different QCovid3 thresholds of absolute risk)
Cumulative proportion (%) of deaths based
on absolute risk (sensitivity)*
Total No of cumulative deathsThreshold predicted absolute risk (%) at 70
days







* Sensitivity calculated as the total cumulative number of patients with a risk score above the risk threshold with a covid-19 death at 70 days divided by the total cumulative number of patients with a covid-19 death at 70
days.
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Table 4 | Characteristics of patients at highest risk of covid-19 related death (top 5%) from 14 days after covid-19 vaccination in the validation cohort
using QCovid3 model. Data are numbers (percentages) unless stated otherwise
Patients not in top 5% highest risk of covid-19 death
(n=546 281)
Patients in top 5% highest risk of covid-19 death (n=28
751)
Characteristics
14 days after vaccination:
49 (0.01)115 (0.40)Covid-19 related death
86 (0.02)86 (0.30)Covid-19 related hospital admission
Sex:
290 694 (53.21)12 627 (43.92)Women
255 587 (46.79)16 124 (56.08)Men
53.39 (15.52)85.48 (5.65)Mean age (SD)
0.01 (3.05)−0.21 (2.94)Mean Townsend deprivation score (SD)
27.76 (5.68)27.23 (5.50)Mean body mass index (SD)
Ethnic origin:
463 902 (84.92)26 508 (92.20)White
18 339 (3.36)848 (2.95)Indian
8441 (1.55)402 (1.40)Pakistani
4063 (0.74)53 (0.18)Bangladeshi
9178 (1.68)158 (0.55)Other Asian
6275 (1.15)434 (1.51)Caribbean
14 708 (2.69)52 (0.18)Black African
3590 (0.66)26 (0.09)Chinese
17 785 (3.26)270 (0.94)Other
Chronic kidney disease:
528 091 (96.67)18 259 (63.51)None
16 640 (3.05)9237 (32.13)Stage 3
609 (0.11)827 (2.88)Stage 4
387 (0.07)309 (1.07)Stage 5 only
161 (0.03)52 (0.18)Stage 5 with dialysis
393 (0.07)67 (0.23)Stage 5 with transplantation
Chemotherapy:
543 184 (99.43)28 035 (97.51)None in past 12 months
1242 (0.23)144 (0.50)Group A
1712 (0.31)536 (1.86)Group B
143 (0.03)36 (0.13)Group C
Type 2 diabetes:
501 199 (91.75)20 607 (71.67)No type 2 diabetes
29 176 (5.34)5794 (20.15)HbA1c ≤59 mmol/mol (≤7.5%)
15 906 (2.91)2350 (8.17)HbA1c >59 mmol/mol (>7.5%)
Other pre-existing health conditions:
2824 (0.52)838 (2.91)Blood cancer
133 (0.02)21 (0.07)Bone marrow or solid organ transplant
1034 (0.19)377 (1.31)Respiratory cancer
646 (0.12)219 (0.76)Recent radiotherapy
319 (0.06)39 (0.14)Down’s syndrome
15 265 (2.79)4018 (13.98)Chronic obstructive pulmonary disease
20 457 (3.74)7489 (26.05)Coronary heart disease
11 039 (2.02)4627 (16.09)Stroke
11 266 (2.06)5986 (20.82)Atrial fibrillation
4694 (0.86)3316 (11.53)Heart failure
10 322 (1.89)2545 (8.85)Venous thromboembolism
1407 (0.26)3698 (12.86)Dementia
987 (0.18)635 (2.21)Parkinson’s disease
9286 (1.70)549 (1.91)Epilepsy
2131 (0.39)220 (0.77)Rare neurological conditions
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Table 4 | Characteristics of patients at highest risk of covid-19 related death (top 5%) from 14 days after covid-19 vaccination in the validation cohort
using QCovid3 model. Data are numbers (percentages) unless stated otherwise (Continued)
Patients not in top 5% highest risk of covid-19 death
(n=546 281)
Patients in top 5% highest risk of covid-19 death (n=28
751)
Characteristics
1188 (0.22)253 (0.88)Liver cirrhosis
196 (0.04)12 (0.04)Sickle cell disease
1667 (0.31)36 (0.13)HIV/AIDS
280 (0.05)22 (0.08)Severe combined immunodeficiency
SD=standard deviation; HbA1c=glycated haemogoblin. Chemotherapy groups are defined in supplementary box A of reference 1.
Box 1: Clinical examples of patients and their predicted covid-19 risks
over a 70 day period, based on QCovid3 risk algorithms
(https://bmjSept2021.qcovid.org)
Example 1
72 year old white man with a first vaccine dose, atrial fibrillation, and
body mass index of 30 (background daily infection rate of 22 positive
reverse transcription polymerase chain reaction (RT-PCR) test results per
100 000 people) would have:
• 0.04% risk of covid-19 related hospital admission over a 70 day period
• 0.02% risk of covid-19 death over a 70 day period
• 5.15% risk of covid-19 related death after a SARS-CoV-2 positive test
result.
Example 2
62 year old Pakistani woman with two vaccine doses, chronic kidney
disease stage 5 with transplantation, and body mass index of 24
(background daily infection rate of 20 positive RT-PCR test results per
100 000 people) would have:
• 0.04% risk of covid-19 related hospital admission over a 70 day period
• 0.003% risk of covid-19 death over a 70 day period
• 0.10% risk of covid-19 related death after a SARS-CoV-2 positive test
result.
Example 3
60 year old white man with a first vaccine dose, stroke, epilepsy, well
controlled type 2 diabetes, Down’s syndrome, and body mass index of
41 (background daily infection rate of 60 positive RT-PCR test results per
100 000 people) would have:
• 0.56% risk of covid-19 related hospital admission over a 70 day period
• 0.46% risk of covid-19 death over a 70 day period
• 24.3% risk of covid-19 related death after a SARS-CoV-2 positive test
result.
Example 4
67 year-old Caribbean woman with a first vaccine dose, liver cirrhosis,
and body mass index of 41 (background daily infection rate of 40 positive
RT-PCR test results per 100 000 people) would have:
• 0.08% risk of covid-19 related hospital admission over a 70 day period
• 0.04% risk of covid-19 death over a 70 day period
• 7.29% risk of covid-19 related death after a SARS-CoV-2 positive test
result.
QCovid2 model in unvaccinated patients
Supplementary figure 7 shows the adjusted hazard ratios for risk
of covid-19 death for men and women in the comparison cohort of
unvaccinated individuals using theQCovid2model. Supplementary
figure 8 shows the corresponding results for covid-19 hospital
admission. Thesemodels areupdatedversionsof theoriginalQCovid
model from our earlier publication.1 The new models include
additional variables for inflammatory bowel disease, levels of
diabetes control (according to measured HbA1c values), separate
variables for sickle cell disease, HIV/AIDS, and severe combined
immunodeficiency, and a refined definition of severe mental illness
(whichnow includes only schizophrenia or bipolar disease but does
not include moderate and severe depression).
The hazard ratios for QCovid2 were generally similar in magnitude
and direction for the subset of variables included in our main model
(QCovid3). However, some additional variables included in the
QCovid2 model did not reach statistical significance or resulted in
hazard ratios lower than 1.1, and hence were not included in the
main QCovid3 model. These variables were type 1 diabetes, asthma,
rare lungconditions,pulmonary fibrosis orpulmonaryhypertension,
congenital heart disease, cerebral palsy, inflammatory bowel
disease, and severe mental illness (schizophrenia or bipolar
disorder).
Supplementary table 3 shows similar performance statistics for
discrimination and explained variation for the main QCovid2 model
when compared with the original QCovid model evaluated in the
validation cohort. Supplementary figures 9 and 10 show adjusted
hazard ratios from a similar analysis for risk of covid-19 death and
hospital admission in unvaccinated patients but restricted to
individuals with a positive SARS-CoV-2 test result.
Discussion
Principal findings
We have identified a range of important clinical risk factors for
severe covid-19 outcomes in people in the UK, 14 days or more after
covid-19 vaccination (first or second dose) when some immunity is
expected to have developed. We have used national linked datasets
from general practice, national immunisation and SARS-CoV-2
testing, death registry, and hospital episode data for a population
representative sample of more than 6.9 million adults. Risk ratios
were highest for people with Down’s syndrome, kidney
transplantation, sickle cell disease, care home residency,
chemotherapy, recent bone marrow transplantation or solid organ
transplantation ever, HIV/AIDS, dementia, Parkinson’s disease,
neurological conditions, and liver cirrhosis. We also developed and
evaluated novel clinical risk prediction models to estimate the
absolute risks of covid-19 related hospital admission and mortality
in the general population of vaccinated people as well as in the
subset of people with positive SARS-CoV-2 test results. The risk
models showed high levels of discrimination (C statistics ≥0.88 for
the primary outcome, covid-19 death) and good calibration.
For many of the predictors included in the original QCovid model
(contributing to risk prediction in an unvaccinated population
during wave 1), the magnitude of the relative risks is broadly
comparable in both QCovid2 (risk prediction in an unvaccinated
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population, wave 2) and QCovid3 (risk prediction in a vaccinated
population, wave 2). Although these associations cannot be given
a causal interpretation, individual characteristics such as age,23
obesity, pre-existing medical conditions, and socioeconomic
disadvantage24 are known to affect immune competence25 and, at
least for certain diseases, affect the response to some vaccines26 -30
or to immunosuppressive drugs.7 31 The associations with Down’s
syndrome in all the models are likely to reflect increased
susceptibility to infection and genetic predisposition.8 Compared
with the white ethnic group, the Pakistani and Indian groups had
up to twofold increased hazards of covid-19 death and hospital
admission after vaccination in the full QCovid3 model. These ethnic
disparities in covid-19 outcomes could represent residual differential
exposure (eg, linked to behaviour, lifestyle, household size, and
occupation) more than differential susceptibility mechanisms,32
although we also acknowledge that being vaccinated could change
behaviour (and exposure) in some groups more than in others.
These risk models can be deployed in several health and care
settings, either during the current phase of the pandemic or in
subsequent waves of infection (with recalibration as required);
however, absolute risk for individualswill alwaysdependondisease
prevalence and personal exposures. Uses of QCovid3 could include
supporting targeted recruitment for clinical trials, prioritisation of
vaccine boosters, future preventive treatments such as prophylactic
passivemonoclonal antibodyprotection, shielding, anddiscussions
between individuals and clinicians on workplace or health risk
mitigation (eg, through improved glycaemic control, weight
reduction,33or general risk avoidance behaviours). Our QCovid3
model provides absolute risks conditional onpatient characteristics,
including whether they have received one or two doses of a covid-19
vaccine, and on the underlying prevailing infection levels. It also
enables individuals to be ranked in terms of their risk. The
deployment of drug and non-drug interventions to protect
individuals with residual vulnerability after vaccination needs to
be considered in the context of absolute risks of severe outcomes
at the time of making predictions. Absolute risks are related to both
the prevalence of SARS-CoV-2 infection in the population and the
likelihoodof SARS-CoV-2 exposure in avaccinatedadult population.
Although these algorithmshavebeendesigned to informUKhealth
policy and interventions tomanage covid-19 related risks, they also
have international potential, subject to local validation. Previous
similar risk prediction models have been validated internationally
and shown to have good performance outside of the UK.34 35
Strengths and limitations of this study
Our study has some major strengths but also some important
limitations, which include specific issues related to covid-19 along
with factors similar to those for several other widely used clinical
risk prediction algorithms developed using the QResearch
database.36 -38 Key strengths included the use of large, validated,
representative, population based contemporaneous data sources
that have been used to develop other widely used risk prediction
tools36 37; the wealth of candidate risk predictors; the prospective
recording of outcomes and their ascertainment using linkage of
multiple national databases; lack of selection, recall, and
respondent biases; and robust statistical analysis. We have used
non-linear terms to model body mass index, age, and background
SARS-CoV-2 infection rates. The inclusion of infection rates is a
substantial improvement comparedwith theoriginalQCovidmodel,
because it enables risks to be updated according to the background
infection, which is important given the nature of pandemic waves.
Our analysis has been able to separately quantify the risk of severe
outcomes among those people with a positive SARS-CoV-2 test
result, which was not possible in the original QCovid model1 owing
to a lack of testing data. Therefore, the analysis could be used at
the point of testing to identify those who might benefit from
additional interventions such asmonoclonal antibodies once these
treatments become available.
Limitations included a relatively short duration of follow-up, a
partially vaccinated population, and small numbers of events in
somesubgroups—whichare inevitable consequencesofundertaking
an analysis during rapid deployment of a national vaccination
programme. Our analysis incorporated information on whether an
individual had received one or two vaccination doses in our
prediction models. We saw relatively few deaths in individuals who
had received the second dose of the vaccine (4% of all covid-19
related deaths); therefore, most information about associations
between predictors and mortality came from individuals who had
received only one dose. Results from individuals who have received
the second vaccination dose are likely to be most relevant for UK
adults as full vaccine coverage increases. Although we examined
for interactions, our study might have lacked power to detect
whether certain associations differed according to whether one or
two doses had been received. Our models also incorporated
information on prevailing positive SARS-CoV-2 infection rates, as
a proxy for a person’s risk of covid-19 infection at the start of the
follow-up period.
We did not include information on different variants that emerged
during the study period owing to incomplete data, particularly in
those patients admitted to hospital.39 While we accounted for many
risk factors for covid-19 mortality, some risks could remain, such
as those conferred by rare medical conditions or other factors
associated with exposure (eg, occupation) that are poorly recorded
in general practice or hospital records and that might be being
proxied to some extent by the covariates included. We did not
distinguish vaccination type because this study was not designed
to compare vaccine effectiveness. Younger patients without
underlying health conditions had limited data, because the
vaccination programme in England prioritised elderly patients and
those people at highest risk. Furthermore, those patients who had
two vaccines early in the pandemic were judged to be at highest
risk of infection or severe outcomes.
Although we have reported a validation using practices from
QResearch, these practices were separate to those used to develop
the model. Previously we have used this approach to develop and
validate other widely used prediction models. When these models
have been validated on different clinical computer systems, the
results havebeen similar.40 -42 Work is alreadyunderway to evaluate
the new models in external datasets (such as the English national
dataset hosted by the Office for National Statistics) including data
from other general practice computer systems that have not been
used to derive the algorithm. These data offer a fully independent
dataset including data from general practice computer systems not
included in the derivation of the dataset. They also offer a larger
sample size for validation because clinical and demographic
subgroupswill havemore events.Work is alsounderway to consider
integration of this new algorithm within NHS clinical software
systems.
Policy implications and conclusions
This study presents a robust risk prediction model (QCovid3) that
can be used to stratify risk populations to identify those who are at
highest risk of severe covid-19 outcomes despite covid-19
vaccination, and who might therefore benefit from further
interventions to reduce risk or boost immunity once these become
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available. The model can be used in conjunction with QCovid2,
which updates and replaces the original algorithm (QCovid1) and
is designed for use in unvaccinated patients. We anticipate that
these algorithms will be updated as the vaccination programme
progresses and is extended to younger agegroups, asunderstanding
of covid-19 increases, as more post-vaccination follow-up data
become available, as new variants of concern emerge, and in
response to new policy interventions.
What is already known on this topic
• The original QCovid tool for predicting risk of covid-19 related death
or hospital admission based on individual characteristics was used
in England to identify patients at high risk of severe covid-19 outcomes
• Identification of these high risk patients added an additional 1.5
million people to the national shielded patient list in February 2021
• On a UK basis, these patients would be prioritised for vaccination, if
they had not already been offered the vaccine on account of their age
or occupation
What this study adds
• Commissioned by the Chief Medical Officer for England on behalf of
the UK government, two new risk prediction algorithms have been
derived and validated to estimate the risk of covid-19 related mortality
and hospital admission in UK adults, 14 days or more after vaccination
when some immunity is expected to have developed
• Several clinical risk factors for severe covid-19 outcomes despite
vaccination have been identified: Down’s syndrome, kidney
transplantation, sickle cell disease, care home residency,
chemotherapy, recent bone marrow transplantation or a solid organ
transplantation ever, HIV/AIDS, dementia, Parkinson’s disease,
neurological conditions, and liver cirrhosis
• The QCovid3 risk algorithms (https://bmjSept2021.qcovid.org) showed
high levels of discrimination for identifying adults at highest risk of
covid-19 related death and hospital admission after vaccination; these
risk stratification tools can help support public health policy and
prioritise patients for targeted, early interventions
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